ZINC (Zn) is an essential trace mineral that plays an important role in DNA synthesis, protein synthesis, mitosis and cell division (39) . During lactation in humans, the mammary gland must transfer an extraordinary amount of Zn to meet the daily requirements of growing infants. This amounts to the transfer of ϳ1-2 mg Zn across the mammary gland into milk, which is almost twice the amount of Zn transferred across the placenta to the fetus during pregnancy (34) . Milk Zn concentration is relatively refractive to maternal Zn intake, indicating that the mammary gland tightly regulates Zn transfer into milk; however, the molecular mechanisms that regulate this process are not understood.
Two superfamilies of mammalian Zn transporters have been identified. The Solute Carrier 39A (SLC39A) gene family encodes Zn transporters (Zip1-14) that function in Zn uptake into the cytoplasm (4, 15, 16, 25, 26, 32, 35, 50 -52, 56) . In contrast, the SLC30A gene family encodes Zn transporters (ZnT1-10) that function in Zn efflux and compartmentalization into intracellular vesicles (4, 24, 25, 29, 35, (42) (43) (44) . ZnT2 (SLC30A2) is associated with a vesicular compartment and presumably functions in Zn sequestration (42) . ZnT2 expression is primarily restricted to highly specialized secretory tissues such as the mammary and prostate glands (24, 28) . Recent studies suggest that ZnT2 is essential for optimal Zn secretion into milk from the mammary gland as a genetic mutation in ZnT2 results in a severe and "transient neonatal Zn deficiency" in exclusively breast-fed infants as a result of low Zn levels in milk (5) . Thus understanding the function and regulation of ZnT2 in the mammary gland will provide important information as to how this highly specialized, hormonally regulated secretory tissue is capable of transferring an extraordinary amount of Zn.
Mammary epithelial cells are the highly specialized secretory cells that tightly coordinate the accumulation, production and secretion of milk components in response to the lactogenic hormone prolactin (PRL) following binding of PRL to prolactin receptors (PRLr) (41) . Circulating PRL levels are positively associated with milk Zn concentration (33) , suggesting that PRL plays a role in regulating Zn secretion from the mammary gland. PRL signaling occurs following the binding of PRL to PRLr. Multiple isoforms of PRLr have been found that have distinct cytoplasmic domains and signaling capabilities (36) . It has been revealed that at least two isoforms of PRLr protein (the long form and short form) are generated by alternative splicing of a single PRLr gene (23) . The classical PRL signaling pathway involves PRLr activation and the recruitment of Jak2 to the cytoplasmic domain of PRLr, leading to autophosphorylation of Jak2 and phosphorylation of PRLr (11, 13, 49) . Second, STAT proteins (including STAT-1, -3, and -5) (12) are phosphorylated by Jak2, which then form homo-or heterodimers and translocate into the nucleus where they bind to specific response elements (GAS sites) in the promoters of target genes (10, 12, 54) . STAT5, also named mammary gland factor, was first found to be involved in the PRL-induced ␤-casein gene expression in mammary glands (54) .
We have previously determined that PRL stimulation plays a role in modulating Zn secretion through increasing ZnT2 protein abundance (Lopez and Kelleher, unpublished observations). However, how ZnT2 is regulated by PRL in mammary epithelial cells is not understood. In the present study, we used cultured mammary cells (HC11) as a model to explore the role of PRL signaling on the expression of ZnT2. This cell line was chosen as a model as it is the only normal mammary epithelial cell line that endogenously expresses long-form of PRLr. Herein we show that the ZnT2 gene is responsive to PRL through activation of the Jak2/STAT5 signaling pathway. We identified two STAT5 elements in the ZnT2 promoter and demonstrated that STAT5 binding to these sites was modulated by PRL in vitro and that these observations can be recapitulated in vivo.
MATERIALS AND METHODS
Cell culture. HC11 cells were a gift from Dr. Jeffery Rosen (Houston, TX) and used with permission of Dr. Bernd Groner (Institute for Biomedical Research, Frankfurt, Germany). Cells were routinely maintained in RPMI 1640 supplemented with 10% fetal bovine serum, epidermal growth factor (EGF, 10 ng/ml), insulin (5 g/ml), and gentamycin (50 g/ml). Cells were treated with PRL (1 g/ml) and cortisol (2 M) in serum-free RPMI 1640 and were pretreated with the specific inhibitors AG490 (10 M) and PD-98059 (10 M) for 4 h where indicated.
RNA isolation and real time PCR. Total RNA was extracted from cells using TRIzol reagent (Invitrogen, Carlsbad, CA) and treated with DNAse I (Roche Applied Science, Indianapolis, IN). Complementary DNA was synthesized using the M-MLV Reverse Transcriptase (Applied Biosystems, Foster City, CA). Fluorescence real-time PCR was performed with iQ SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA) using the MJ Research Opticon 2 system (MJ Research, Waltham, MA). Pfaffl's method was applied for relative quantification of ZnT2 expression normalized to endogenous control (␤-actin) gene (46) . Specific primers for mZnT2 (5Ј-GGCCCGACGCAAACTCTATGT-3Ј, 5Ј-TGCACGGCCAGGTACACACGA-3Ј) and ␤-actin (5Ј-AGCCATG-TACGTAGCCATCC-3Ј, 5Ј-CTCTCAGCTGTGGTGGTGAA-3Ј) were designed using Primer Express Software v2.0 (Applied Biosystems). PCR reactions were run in triplicate (95°C for 10 min, and 40 cycles of 95°C for 15 s, 58°C for 30 s and 72°C for 30 s).
Nuclear run-on assay. Transcriptional regulation of the ZnT2 gene by prolactin was first confirmed following actinomycin D treatment (5 g/ml). A nuclear run-on assay using biotin labeling and real-time quantitative PCR was performed by the method described previously (45) . Briefly, cells were treated with PRL (1 g/ml) for 24 h, after which the cells were trypsinized and resuspended in 4 ml lysis buffer (10 mM Tris ⅐ HCl, pH 7.4, 3 mM MgCl2, 10 mM NaCl, 150 mM sucrose, 0.5% Nonidet P-40, and 1 mM PMSF). After 5 min incubation in ice, nuclei were then collected by centrifugation (170 g) and were kept in 100 l freezing buffer (50 mM Tris ⅐ HCl, pH 8.3, 40% glycerol, 5 mM MgCl2, and 0.1 mM EDTA). In vitro RNA synthesis from DNA was performed for 30 min at 37°C in transcription buffer [20 mM Tris ⅐ HCl, pH 8.0, 100 mM KCl, 2.5 mM MgCl2, 2 mM dithiothreitol (DTT), 100 mM sucrose, and 10% glycerol, 2 mM each of ATP, GTP, and CTP, 1.3 mM UTP]. Biotin-16-UTP (Roche Applied Science) was included in the reaction mixture for detection of newly transcribed RNA and RNA was isolated with TRIzol reagent. The biotinylated transcripts were captured on streptavidin-coated magnetic beads and eluted in diethylpyrocarbonate (DEPC)-treated water. Total cDNA was then synthesized by random hexamer-primed reverse transcription of captured biotinylated nascent RNA. Quantitative real-time PCR was performed to monitor the transcript abundance of ZnT2.
Plasmid constructs. The putative promoter of mouse ZnT2 (Ϫ988 bp upstream from the putative start codon) was amplified by PCR from the genomic BAC clone (RP23-204E6) with primers (forward: 5Ј-ATAGGTACCTCCGTTGAAGGTCCCACATC-3Ј, reverse: 5Ј-ATACTCGAGTCGGTGCGCCCTCGAAGTT-3Ј) and subcloned into the pGL3-basic vector (Promega, Madison, WI) via KpnI and XhoI restriction sites (pGL3-ZnT2-988). Two putative STAT5 binding elements (GAS elements) were identified in the promoter of ZnT2 (PROMO sever). Mutagenesis was performed using the Phusion Site-Directed Mutagenesis Kit (New England Biolab, Beverly, MA), and the following mutants were generated and sequence verified: pGL3-ZnT2-GAS1M [deletion of the putative GAS1 element (TTCCAGGAA) at position Ϫ674 to Ϫ665]; pGL3-ZnT2-GAS2M [deletion of the putative GAS2 element (TTCCAGGAA) at position Ϫ377 to Ϫ368]; and pGL3-ZnT2-GAS12M (deletion of both GAS1 and GAS2 elements). Plasmids pcDNA3/STAT5a and pcDNA3/PRLr, which express STAT5a and longform PRLr, respectively, were constructed using PCDNA3.1/V5-His TOPO TA Expression Kit (Invitrogen). Expression vector for dominant-negative STAT5 (DNSTAT5) was generated as previously described (57) .
Transient transfection and luciferase assay. All plasmids were purified using the GenElute HP plasmid Midiprep Kit (Sigma) and quantitated by UV spectrophotometry. Cells were seeded in 24-well plates and transfected with either pGL3-ZnT2-988, pGL3-ZnT2-GAS1M, pGL3-ZnT2-GAS2M, pGL3-ZnT2-GAS12M, or pGL3-basic (vector control) using Lipofectamine 2000 (Invitrogen). Cells were transfected with either wtSTAT5a or the long-form of PRLr (or both) to amplify the luminescence where indicated. Cells were cotransfected with DNSTAT5 to inhibit the wtSTAT5-mediated signaling where indicated.
Twenty-four hours after transfection, cells were treated with PRL (0.3, 0.6, 1.2, 2.4, and 4.8 g/ml) for 24 h. PRL (1 g/ml) was found to be the optimal concentration for maximal ZnT2 promoter activation. The cells were harvested and lysed in passive lysis buffer (125 l/well). Luciferase activity was measured using the Dual Luciferase Reporter Assay System (Promega). The relative firefly luciferase activity was normalized by Renilla luciferase activity. Each experiment was repeated at least three times.
Electrophoretic mobility shift assays. Cells were cultured in serumfree media and then stimulated with PRL (1 g/ml) for various times (1, 2, and 8 h) before harvesting nuclear protein extracts (NPE) as described previously (8) . Oligonucleotides containing GAS1 (5Ј-ATCCAATTCCAGGAAGTCTCT-3Ј) and GAS2 (5Ј-ACAGGAT-TCCAGGAAGAGTGG Ϫ3Ј) were end-labeled using [␥-
32 P]ATP (Perkin Elmer, Waltham, MA) and incubated in binding buffer (10 mM HEPES, 100 mM KCl, 0.05 mM EDTA, 2.5 mM MgCl2, and 6% glycerol) with NPE (2 g) and poly(dI-dC) (80 g/ml) for 15 min at room temperature. The end-labeled, double-stranded oligonucleotide (5Ј-GCAGATTTCTAGGAATTCAAA-3Ј), harboring a consensus GAS element that exists in bovine ␤-casein promoter, was used as a positive control. Nonradioactive oligonucleotide competitor (GAS1: ATCCAATTCCAGGAAGTCTCT; GAS2: 5Ј-ACAGGATTCCAG-GAAGAGTGG-3Ј) was generated by annealing unlabeled primers and added to binding reactions in 60-fold molar excess. The mutant competitor (GAS1: ATCCAATTATTTTAAGTCTCT; GAS2: 5Ј-ACAGGATTATTTTAAGAGTGG-3Ј), harboring mutation of the putative GAS element, was also generated and included in the binding reaction in the indicated group. For supershift assay, NPE were preincubated for 30 min with 2 l STAT5 antibody (Cell Signaling Technology, Danvers, MA). Samples were electrophoresed through a 7.5% nondenaturing polyacrylamide gel. After electrophoresis, the gels were dried and exposed to autoradiography film at Ϫ70°C.
Chromatin immunoprecipitation assays. Cells were cultured in serum-free media and then stimulated with PRL (1 g/ml) for 1, 2, and 8 h. Cells were then incubated with 1% formaldehyde for 20 min at room temperature to cross-link proteins to the DNA and washed with cold PBS buffer before lysis with SDS lysis buffer (50 mM Tris ⅐ HCl, pH 8.0, 1% SDS, 10 mM EDTA, 1 mM PMSF, and 1 mM Na3VO4). Cell lysates were sonicated on ice to shear chromatin and diluted in chromatin immunoprecipitation (ChIP) assay dilution buffer (16.7 mM Tris ⅐ HCl, pH 8.0, 0.01% SDS, 1% Triton X-100, 1.2 mM EDTA, and 167 mM NaCl). Fifty microliters of each diluted chromatin sample was collected as the input DNA. The rest of chromatin suspension was precleared with Protein A-agarose slurry containing salmon sperm DNA for 30 min and then incubated with either STAT5 antibody or normal rabbit IgG (control) overnight at 4°C with rocking. The agarose beads were collected by centrifugation and washed sequentially for 5 min with each of the following four buffers: low-salt wash buffer, high-salt wash buffer, LiCl wash buffer, and TE buffer. Immunoprecipitated DNA was eluted with 200 l elution buffer (1% SDS and 0.1 M NaHCO 3). Cross-linking was reversed by heating at 65°C for 4 h, and samples were digested with protease K and purified by phenol-chloroform extraction and ethanol precipitation. Quantitative real-time PCR was used to quantitate both the input DNA and ChIP DNAs using ZnT2 promoter primers (5Ј-CTGTCACTCCCT-TGCACCAA-3Ј; 5Ј-GTTGCTAAGTTAGGACTGGATGA-3Ј). ChIP data are expressed as percentage of input DNA (amount of ChIP DNA PCR product divided by that of the input DNA).
Statistical analysis. Data represent means Ϯ SE. Statistical significance for each experimental comparison was determined using Student's t-test or one-way ANOVA, with P Ͻ 0.05 considered a significant effect of treatment.
RESULTS

PRL induces ZnT2 expression in HC11 cells.
In this study, we used normal mammary epithelial cells that endogenously express PRLr to determine whether ZnT2 expression is regulated at the transcriptional level by PRL. Cells were treated with PRL (1 g/ml) for up to 24 h, and ZnT2 mRNA level was quantified by real-time PCR. PRL treatment significantly increased ZnT2 mRNA level (fivefold) compared with untreated cells. (Fig. 1A) . To evaluate whether the PRL-induced increase in ZnT2 mRNA level resulted from increased transcription of the ZnT2 gene or mRNA stability, we coincubated the cells with PRL (1 g/ml) and actinomycin D (5 g/ml) for 24 h. Treatment with actinomycin D, which blocks the function of the transcriptional machinery, completely abolished the PRLinduced upregulation of ZnT2 mRNA in HC11 cells, indicating that PRL regulates ZnT2 by a RNA polymerase-dependent transcriptional mechanism (Fig. 1B) . To further determine whether the increase in ZnT2 mRNA level we detected in response to PRL stimulation resulted from increased transcription of the ZnT2 gene, we next performed a nuclear run-on assay in isolated nuclei from cells treated with PRL (1 g/ml). Importantly, we detected a significant increase in the rate of ZnT2 gene transcription in cells treated with PRL (Fig. 1C) . These data clearly indicated that PRL stimulation increased ZnT2 transcription and thus we next aimed to determine the signaling mechanisms responsible for this effect.
AG490 reduced effects of PRL treatment on ZnT2 mRNA level. Both the Jak2/STAT5 and MAPK signaling pathways have been reported to be important for PRL signal transduction in cells of mammary epithelial origin (13, 48) . To determine which signaling pathway plays a role in the transcriptional regulation of the ZnT2 gene, HC11 cells were pretreated with the Jak2 inhibitor AG490 (10 M) or the MAPK inhibitor PD-98059 (10 M) for 4 h before PRL treatment to inhibit Jak2 or MAPK signaling. After the 4-h pretreatment, the HC11 cells were treated with PRL for an additional 24 h. The results showed that chemical inhibition of Jak2 eliminated the PRLinduced increase in ZnT2 mRNA abundance (Fig. 2) . In contrast, no effect of MAPK inhibition was observed. These findings strongly suggested that the transcriptional activation of ZnT2 in mammary cells by PRL is Jak2/STAT5 dependent.
PRL induced the transcriptional activity of ZnT2 promoter through involvement of STAT5. To determine the mechanisms through which Jak2/STAT5 mediates the activation of ZnT2 /ml) for 24 h. Nuclei were isolated, and in vitro biotinylated transcripts were measured by real-time PCR using specific primers. Data are expressed as means Ϯ SE after normalization with ␤-actin expression as an internal standard. Samples were analyzed in triplicate and experiments were repeated more than three times. *Significant effect of treatment, P Ͻ 0.05. transcription, we explored ZnT2 promoter activation by PRL using a luciferase reporter assay. A 988-bp fragment of the wild-type ZnT2 promoter was subcloned into the pGL3-basic luciferase reporter vector. Cells were transfected with the ZnT2 full-length promoter construct (pGL3-ZnT2-988) or with the empty vector as a control and then treated with PRL (1 g/ml) for 24 h. Activation of the ZnT2 promoter was measured by the luciferase activity, and the result indicated that the promoter was only slightly increased in HC11 cells treated with PRL. To amplify the luminescence, we utilized an artificial cell system in which we overexpressed either the long-form of PRLr or STAT5a (or both) to exacerbate the response to PRL. The results showed that the introduction of either long-form PRLr or STAT5a significantly enhanced the PRL-induced luciferase activity, and cotransfection of both PRLr and STAT5a resulted in the most robust increase in luciferase activity (P Ͻ 0.05) (Fig. 3A) .
To verify a role for STAT5 in this response we next generated a dominant negative STAT5 construct, which is a COOH-terminal truncated mutant (STAT5a⌬713) that acts as a dominant negative mutant for STAT5 by forming inactive heterodimers with wild-type STAT5 proteins (55) . Coexpression of DNSTAT5 with the ZnT2 promoter construct resulted in both decreased basal and PRL-induced luciferase activity (Fig. 3B) . Together, these results indicate that the enhanced transcription of the ZnT2 gene resulting from PRL stimulation results from activation of the Jak/STAT signaling pathway through STAT5a.
Identification of two functional STAT5 binding sites in the ZnT2 promoter. We next aimed to determine how STAT5 elicited the activation of the ZnT2 promoter. Genes that respond directly to PRL often possess canonical STAT5 response elements (GAS), most often located in the region upstream of the transcription start site (1, 2) . The canonical GAS element is composed of the consensus sequence 5Ј-TTCNNNGAA-3Ј. In the presence of PRL, PRLr signaling can activate STAT5, which then form homo-or heterodimers that translocate into the nucleus where they bind to the GAS element in the promoters of target genes. Analysis of the 5Ј-untranslated region of the ZnT2 gene revealed that the ZnT2 promoter contains two putative GAS elements within this region, a distal GAS1 element (from Ϫ674 to Ϫ665) and a proximal GAS2 element (from Ϫ377 to Ϫ368) (Fig. 4A) .
To verify the functional relevance of these putative GAS elements, both GAS1 and GAS2 elements were mutated as illustrated in Fig. 4A , and cells were transfected with either the wild-type promoter construct ZnT2PFL (pGL3-ZnT2-988) or the mutated promoter constructs GAS1M (pGL3-ZnT2-GAS1M) or GAS2M (pGL3-ZnT2-GAS2M) or GAS12M (pGL3-ZnT2-GAS12M). PRLr and STAT5a constructs were cotransfected to enhance PRL signaling. Cells were then treated with varying doses of PRL (0, 0.3, 0.6, 1.2, 2.4, and 4.8 g/ml) and luciferase Fig. 3 . ZnT2 promoter activity is induced by PRL in a STAT5a-dependent manner. A: activation of ZnT2 promoter by PRL stimulation. ZnT2 promoter luciferase construct (0.8 g) was transfected into HC11 cells. Mammalian expression constructs for either PRLr (0.2 g) or STAT5a (0.2 g) (or both) was overexpressed in the indicated groups. Luciferase activity was assessed following 24 h treatment with PRL (1 g/ml). Samples were analyzed in triplicate and experiments were repeated more than three times. *Significant effect of treatment, P Ͻ 0.05. B: dominant-negative STAT5 (DNSTAT5) impairs activation of the ZnT2 promoter by PRL. HC11 cells were transfected with ZnT2 promoter luciferase construct (0.8 g) and the mammalian expression constructs for PRLr (0.2 g) and STAT5a (0.2 g). The DNSTAT5 construct (0.2 g) was overexpressed in the indicated groups. The cells were then stimulated with PRL (1 g/ml) for 24 h. Luciferase activity was normalized relative to the Renilla internal control. Data are expressed as means Ϯ SE. Samples were analyzed in triplicate and experiments were repeated twice. *Basal promoter activity for cells transfected with DNSTAT5 was significantly less than that in non-DNSTAT5-transfected cells. †Stimulation change for PRL-treated cells transfected with DNSTAT5 was significantly lower than that in PRL-treated, non-DNSTAT5-transfected cells, P Ͻ 0.05. activity was measured after 24 h treatment. As illustrated in Fig.  4B , addition of PRL increased luciferase activity in a dosedependent manner only in cells transfected with the wild-type promoter. In comparison, mutation of either the GAS1 or GAS2 element resulted in a substantial reduction in PRL-induced ZnT2 promoter activity. Moreover, the promoter harboring the GAS1 mutation was able to respond to very high PRL concentrations. Elimination of both GAS1 and GAS2 elements completely eliminated PRL-stimulated ZnT2 promoter activity, suggesting that a cooperative relationship exists between the GAS1 and GAS2 elements for PRL-induced activation. It is interesting to note that the proximal GAS2 element appears more important to PRL stimulation as the GAS2 mutant resulted in a complete abrogation in activity beyond that of the distal GAS1 element.
To confirm that these two GAS elements in the ZnT2 promoter are targets for STAT5 binding, we performed gel electrophoretic mobility assays using nuclear proteins isolated from cells that had been treated with PRL for 1, 2, 8, and 24 h (Fig. 5A ). As illustrated in Fig. 5A , a strong protein-DNA complex was detected following incubation with a GAS2-specific oligonucleotide probe (Fig. 5A, lane 7 to lane 12) . In contrast, a very weak binding complex was detected using a GAS1-specific oligonucleotide probe (Fig. 5A, lane 1 to  lane 6) . Because it was very difficult to visualize the GAS1-protein complex at the same exposure level as the GAS2-protein complex, we extended the exposure time to visualize GAS1 binding (Fig. 5A, inset) . This confirmed that the distal GAS1 element has the capability to form a protein-DNA complex similar in size to the GAS2 complex, although the binding affinity was much lower than for GAS2. To verify that the GAS2-DNA complex was specific, Fig. 5B illustrates that the GAS2 complex was competed by 60-fold molar excess of unlabeled GAS2 oligonucleotide probe (Fig. 5B, lane 3) but not by the mutant GAS element (Fig. 5B, lane 4) . A supershift assay was also performed to investigate the specific binding of STAT5 protein to the GAS2 element. These data clearly illustrated that the mobility of the nuclear protein complex was retarded following preincubation with STAT5 antibody (Fig. 5B, lane 5) . Similarly, the specificity of the GAS1-DNA complex was verified under the same conditions except these experiments required a longer exposure time (Fig. 5C ). Our data further revealed that a time lapse in DNA binding to GAS1 does not occur in response to PRL activation. STAT5 binding activity could be detected 2 h following PRL addition (Fig. 5A , lane 10) and reached a maximum at 8 h (Fig. 5A, lane 11) . Longer treatment resulted in a decrease of STAT5-DNA binding activity (Fig. 5A, lane 12) . In contrast, STAT5-DNA binding in complex with GAS1 has almost the same response pattern but with much less sensitivity (Fig. 5A,  inset) .
PRL induced STAT5 recruitment to ZnT2 promoter in vivo.
Results from the in vitro gel shift experiments demonstrated a specific interaction between STAT5 and both GAS elements in the ZnT2 promoter following treatment with PRL. To verify that STAT5 binds specifically to the ZnT2 promoter in vivo, we stimulated cells with PRL for different periods of time (1, 2, and 8 h) and performed ChIP analysis using STAT5 antibody or normal rabbit IgG. Genomic DNA fragments, which were immunoprecipitated with STAT5 antibody or normal rabbit IgG, were then analyzed by quantitative real-time PCR to assess the binding capability of STAT5 to DNA in vivo. As Fig. 6 illustrates, binding of STAT5 to the ZnT2 promoter was specific as immunoprecipitation with normal rabbit IgG was extremely low compared with immunoprecipitation with STAT5-specific antibody. Our data indicated that STAT5 indeed binds to the ZnT2 promoter following PRL stimulation in vivo. Although a modest increase on STAT5 recruitment was detected in as little as 1 h following PRL stimulation, this difference was not statistically significant until 8 h (Fig. 6) . Taken together, results from this study clearly indicate that PRL increases the transcription of ZnT2 through the stimulation of the Jak2/STAT5 signaling cascade.
DISCUSSION
Adequate transfer of Zn to the neonate during the lactating period is essential for optimal offspring development. The importance of optimized Zn secretion into milk is illustrated by Fig. 4 . Two GAS elements in the ZnT2 promoter cooperatively respond to PRL stimulation. A: diagram illustrating the ZnT2 promoter luciferase constructs and putative GAS elements predicted in the ZnT2 promoter region. Deletion mutations were performed on GAS1 (Ϫ674 to Ϫ665) and GAS2 (Ϫ377 to Ϫ368) to eliminate the STAT5 binding sites. B: effects of sitedirected mutagenesis of two putative STAT5 binding sites on ZnT2 promoter activity were measured by luciferase activity assay. HC11 cells were transiently transfected with full-length ZnT2 promoter (ZnT2P), GAS1M, GAS2M, or GAS12M constructs described above and treated with varying doses of PRL (0, 0.3, 0.6, 1.2, 2.4, 4.8 g/ml) for 24 h. The mammalian expression constructs for PRLr (0.2 g) and STAT5a (0.2 g) were cotransfected in all of the groups, with the luciferase reporter plasmid (0.8 g). The data were normalized by Renilla luciferase as an internal standard and are expressed as means Ϯ SE. Samples were analyzed in triplicate and experiments were repeated more than three times. the severe Zn deficiency that occurs in mice pups suckled from dams with a nonsense mutation in the Zn transporter ZnT4 (lethal milk, lm/lm) (24) . In addition, we also identified a mutation in the Zn transporter ZnT2, of which its expression is restricted to several secretory tissues including the mammary gland. This mutation results in reduced Zn secretion into milk and severe neonatal Zn deficiency in human infants (5) . Both ZnT2 and ZnT4 are thought to be localized in intracellular compartments, where they participate in the import of Zn into Golgi, endocytotic, or secretory vesicles (9) , which play a role in Zn release into milk. Previous studies indicate that Zn accumulation in prostate (7) and mammary gland (32) is regulated by reproductive hormones such as testosterone and PRL, which is the result of the regulation of Zip-type Zn transporters. Recently, we also determined that stimulation of cultured mammary epithelial cells with the lactogenic hormone PRL increases Zn secretion, and this effect is associated with higher ZnT2 expression (Lopez and Kelleher, unpublished observations). Thus the aim of this study was to determine how ZnT2 expression is regulated by PRL to aid our understanding of the functional regulation of Zn secretion from the mammary gland during lactation.
It has been well documented that Jak2 and STAT5 are the major molecules mediating PRL induction of target gene expression in a variety of tissues, including the mammary gland (17) . PRL has been shown to increase the secretion of milk proteins such as whey acidic protein, ␤-casein, and ␤-lactoglobulin through the Jak2/STAT5 signaling pathway, (18, 19, 37) . PRL is also responsible for increasing the secretion of trace minerals, such as iron, copper, and Zn into the milk (3, 31, 32) , by inducing metal transporters in mammary epithelial cells. Herein, our data showed that ZnT2 mRNA expression can be induced by PRL in mammary epithelial cells. However, the increase in the steady-state level of ZnT2 mRNA expression may be the result of increased transcription of the ZnT2 gene and/or an increase in ZnT2 mRNA stability. We found that exposure to actinomycin D at the time of initiation of PRL treatment completely abolished PRL-stimulated accumulation of ZnT2 mRNA, which indicates that this upregulation is transcriptionally dependent. Moreover, results from nuclear run-on assays indicated that de novo mRNA synthesis is required for PRL-stimulated ZnT2 mRNA induction to occur. Together these results support our interpretation that at least one mechanism through which Zn secretion is increased in response to PRL stimulation is through the transcriptional regulation of the ZnT2 gene. Specifically, our data indicated that PRL induces ZnT2 expression in mammary epithelial cells through activation of the Jak2/STAT5 pathway. Both Jak1 and Jak2 are associated with PRL receptor and are activated upon PRL stimulation; however, only Jak2 can be stimulated by PRL in HC11 cells (14) . We found that chemical inhibition of Jak2 with AG490 completely suppressed PRL-stimulated ZnT2 expression, which suggests Jak2 is responsible for PRL stimulation of ZnT2 expression in the mammary gland during lactation. PRL has also been demonstrated to activate signaling through the mitogenactivated protein kinase (MAPK) pathway (47, 48) . Nevertheless, treatment of HC11 cells with the MAPK inhibitor PD-98059 had no effect on PRL-induced ZnT2 expression. This clearly implicates the Jak2/STAT5 pathway in PRLmediated regulation of ZnT2 expression.
STAT5 is composed of two highly homologous isomers, STAT5a and STAT5b, sharing ϳ96% amino acid identity (38) . Studies using mice deficient in either STAT5a or STAT5b suggest that there may be a level of functional redundancy, although each of them has its own isotype-specific function (20) . For example, STAT5a is mainly expressed in mammary gland and crucial for normal mammary gland development and lactogenesis (27) . In contrast, STAT5b has unique physiological function in mediating the sexually dimorphic patterns of gene expression in the liver (53) . Based on the tissue specificity and functional requirements for STAT5a in mammary glands and the fact that STAT5a overexpression can enhance the PRL responsiveness of the ZnT2 gene, it is most likely that the PRL-stimulated transcriptional regulation of ZnT2 expression is mediated by STAT5a. Two GAS elements (GAS1 and GAS2), which are classical STAT5 binding sites, were identified within the promoter of ZnT2. Mutagenesis of these two GAS elements suggested that maximal responsiveness of ZnT2 activation to PRL stimulation requires the simultaneous presence of GAS1 and GAS2 elements. Although these two elements cooperate, our data documented hierarchical roles in PRL response and promoter-enhancing activity. GAS2 responded much more strongly to PRL stimulation and thus may be more sensitive to PRL activation, whereas GAS1 responds more weakly to PRL stimulation and may be more crucial for enhancing ZNT2 activation. A number of genes have been identified to contain multiple GAS elements in their promoter regions, some of them are tandemly linked with only several nucleotides (30) . For example, glycosylation-dependent cell adhesion molecule 1 (GlyCAM 1) is stimulated by PRL through the synergistic activation of two tandemly linked STAT5 binding sites within the GlyCAM 1 promoter (21). This close spacing facilitates the formation of STAT5 tetramer-DNA complexes. In contrast, the two GAS elements in ZnT2 promoter are separated by 280 nucleotides and thus are likely to be too far away for the formation of a tetramer-DNA complex. This suggests that different machinery might be involved in STAT5-mediated transcriptional activation of ZnT2.
We speculate that the cooperativity of GAS1 and GAS2 may reflect the complex hormonal activation that occurs during lactation. It is important to note that PRL is required for initial mammary gland differentiation and transition to a lactating phenotype (lactogenesis). This secretory phenotype is maintained by an elevated, basal level of PRL secretion from the pituitary gland during lactation (22) . Importantly, PRL secretion is further increased and peaks in 30 min in response to offspring suckling (40) , which serves to 1) enhance milk component production, transport, and secretion into the alveolar lumen in preparation for the subsequent feeding and 2) maintains the secretory phenotype of the mammary gland. We speculate that basal PRL secretion increases and maintains the expression of ZnT2 in differentiated mammary gland through activation of the more sensitive proximal GAS2 element in the promoter. After which, in response to enhanced PRL secretion following suckling, the high PRL level in circulation may activate ZnT2 expression further through binding to the less sensitive distal GAS1 element facilitating the transport of Zn into the milk.
The importance of understanding how ZnT2 is regulated during lactation stems from the fact that we previously identified a genetic mutation in ZnT2 (H54R) as being responsible for the low milk Zn concentration observed in mothers of infants that were afflicted with "transient neonatal Zn deficiency" (5) . Whereas this clearly implicates ZnT2 as playing a major role in Zn secretion from the mammary gland, we cannot rule out the possibility that mutations other than H54R or single nucleotide polymorphisms (SNPs) may be responsible for low milk Zn concentration in other women. Moreover, evidence suggests that mutations or SNPs in promoter region might also be responsible for alterations in gene expression through modifying mRNA transcription and consequently affecting the content of particular nutrient in milk. For example, it has been reported that a SNP in goat ␤-casein promoter region is associated with the absence of ␤-casein in the milk (6) . As our results indicate that ZnT2 is regulated by PRL, we speculate that if the responsivity to PRL stimulation during lactation varies among women, this may also contribute to variations in milk Zn concentration.
In conclusion, our study indicates that PRL is a potent inducer of ZnT2 gene transcription in mammary epithelial cells. PRL regulates ZnT2 expression via Jak2/STAT5 signaling pathway, and the two GAS elements within ZnT2 promoter are essential for the transcriptional regulation by PRL. Together, these data provide direct evidence as to how PRL stimulation increases ZnT2 expression and ultimately facilitates increased Zn secretion into milk and provides important clues as to how nutrient transport into milk may be regulated during lactation to provide optimal nutrition for the nursing offspring.
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